EDIT
Price
$2.60
Change
+$0.03 (+1.17%)
Updated
Nov 3 closing price
Capitalization
399.31M
5 days until earnings call
Intraday BUY SELL Signals
GERN
Price
$0.93
Change
-$0.00 (-0.00%)
Updated
Nov 3 closing price
Capitalization
597.5M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs GERN

EDIT vs GERN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. GERN commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and GERN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Nov 03, 2026

EDIT in downward trend: price may drop because broke its higher Bollinger Band on October 28, 2026

EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 41 of the 42 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 67 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.

Following a +22.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.051). P/E Ratio (-3.939) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for GERN with price predictions
Nov 03, 2026

GERN's RSI Oscillator stays in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in 165 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In 84 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for GERN turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 43 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for GERN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.733) is normal, around the industry mean (3.051). P/E Ratio (-8.455) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (16.670) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (4.250) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT vs GERN: Fundamental Ratings
EDIT
GERN
OUTLOOK RATING
1..100
8556
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6981
P/E GROWTH RATING
1..100
3514
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for GERN (92). This means that EDIT’s stock grew somewhat faster than GERN’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GERN (100). This means that EDIT’s stock grew similarly to GERN’s over the last 12 months.

GERN's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (99). This means that GERN’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (69) in the Biotechnology industry is in the same range as GERN (81). This means that EDIT’s stock grew similarly to GERN’s over the last 12 months.

GERN's P/E Growth Rating (14) in the Biotechnology industry is in the same range as EDIT (35). This means that GERN’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITGERN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (EDIT: $2.60 vs. GERN: $0.93)
Brand notoriety: EDIT and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 66% vs. GERN: 73%
Market capitalization -- EDIT: $399.31M vs. GERN: $597.5M
EDIT [@Biotechnology] is valued at $399.31M. GERN’s [@Biotechnology] market capitalization is $597.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while GERN’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while GERN’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • GERN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GERN is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а 0.00% price change this week, while GERN (@Biotechnology) price change was -19.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

GERN is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-2.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
GERN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
+0.10%
SER - GERN
66%
Loosely correlated
-1.08%
VCYT - GERN
44%
Loosely correlated
+2.63%
TVTX - GERN
40%
Loosely correlated
+0.30%
RYTM - GERN
39%
Loosely correlated
-7.49%
EDIT - GERN
39%
Loosely correlated
+1.17%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
FLUX.X0.0576000.001978
+3.56%
Flux cryptocurrency
ZRX.X0.0959900.001796
+1.91%
0x Protocol cryptocurrency
SHIB.X0.000005N/A
+1.38%
Shiba Inu cryptocurrency
GAL.X0.803060-0.004042
-0.50%
Galatasaray Fan Token cryptocurrency
FRONT.X0.016400-0.001078
-6.17%
Frontier cryptocurrency